DA
RETA

Duality Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Duality Advisers’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-123,844
Closed -$3.27M – 868
2021
Q4 		$3.27M Buy
+123,844
New +$9.58M 0.35% 85
2021
Q1 		– Sell
-4,097
Closed -$506K – 738
2020
Q4 		$506K Buy
+4,097
New +$538K 0.04% 442

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Duality Advisers's RETA Position: Q1 2022 in Review

Duality Advisers sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 123,844 shares — an estimated $3.27M sold.

Duality Advisers first reported a position in RETA in Q4 2020 and held it in 2 quarters. The position peaked at $3.27M in Q4 2021. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

  • Duality Advisers reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
  • Duality Advisers sold 123,844 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $3.27M.
  • Duality Advisers first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 2 quarters.
  • Duality Advisers's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.27M in Q4 2021.
  • 149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on Duality Advisers's 13F filing for Q1 2022, filed 9 May 2022.